LCZ696 not checked

Advanced Accelerator Applications

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
6 active
8 in total · 8 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Neoplasms
Main trialPhase 1/2
“First in Human (FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), distribution, radiation dosimetry, and anti-tumor activity of \[177Lu\]-NeoB in patients with advanced solid tumors known to overexpress GRPR and with \[68Ga\]-NeoB lesion uptake.”In the company’s words, NCT03872778 on ClinicalTrials.gov
Other names
sacubitril · valsartan

Other drugs for Neoplasms

All 2439 drugs for Neoplasms

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 1/2Completed 7 Jan 2025 [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
Phase 4Authorised not given Timely recovery after subclinical heart failure
Phase 4Authorised not given Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy: (REMOVE)
Phase 3Authorised not given Evaluation of the Efficacy of Valsartan in Slowing Down Aortic Root Dilatation in Children and Young Adults with Marfan-type Heritable Thoracic Aortic Diseases – Valsar-TAD, a randomised, double-blind, placebo-controlled multicentre trial
Phase 4Authorised not given Blockade of the renin-angiotensin system in kidney transplant patients with the presence of renal progenitor cells in urine: randomized clinical trial.
Phase 4Ended not given NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial
Phase 4Authorised not given Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial)
Phase 3/4Authorised not given Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow LCZ696

Following is part of Solo: you see every change to LCZ696 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in